Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Case Reports
Share your love
Research Proposes Ranibizumab Over Laser for ROP Treatment
A study led by a University at Buffalo researcher has the potential to revolutionize the treatment of retinopathy of prematurity (ROP), a condition that can lead to blindness in low birthweight premature infants if left untreated. Published in eClinicalMedicine, the…
Novel Gene Therapy Improves Vision in Children with LCA
In a landmark clinical trial, CRISPR-Cas9 gene editing has proven safe and effective in treating a form of inherited blindness, marking a significant milestone in genetic medicine. The multi-site BRILLIANCE trial, involving the Perelman School of Medicine at the University…
EyePoint’s Duravyu Misses Phase 2 NPDR Trial Goal
EyePoint Pharmaceuticals announced the topline results from its phase 2 PAVIA clinical trial, which evaluated the efficacy of Duravyu (vorolanib intravitreal insert), formerly known as EYP-1901, in treating non-proliferative diabetic retinopathy (NPDR). The trial revealed that Duravyu did not achieve…
Emmecell Completes Dosing in Key Corneal Edema Trial
Emmetrope Ophthalmics, a leader in cell-based therapies for severe eye diseases, today announced the completion of the final dose administration in its U.S. clinical trial for EO2002, targeting the treatment of corneal edema. EO2002 Advances Toward Phase 3 This milestone…
Inflammasome Therapeutics Begins GA Clinical Trial
Inflammasome Therapeutics has officially dosed the first patient in a pioneering clinical trial aimed at treating geographic atrophy (GA) resulting from age-related macular degeneration (AMD). This trial, a first-in-class study for a sustained release implant, is sponsored by the University…
Regeneron’s High-Dose Aflibercept Receives FDA Approval
Regeneron has received FDA approval for Eylea HD (aflibercept 8 mg) in a significant development anticipated to substantially extend dosing intervals for patients with retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).…
LumiThera Receives $2.3M NIH Grant for Dry AMD Trial
LumiThera has been granted a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH), totaling up to $2.3 million in funding over a span of 2 years. This NIH/NEI grant is geared towards supporting…
Best Treatment for Uveitic Macular Edema Identified
Repeat corticosteroid injections were found to be more effective in improving vision for individuals with persistent or recurrent uveitis-related macular edema compared to methotrexate or ranibizumab intravitreal injections, according to a recent clinical trial. The corticosteroid treatment exhibited superior results…
Iveric Bio’s Izervay for Geographic Atrophy Approved by FDA
Parent company Astellas Pharma announced that Iveric Bio has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a new complement C5 inhibitor, Izervay stands out as the sole…
Naegis Pharma Funds Novel Eye Drug
Naegis Pharmaceuticals Inc., a life sciences company specializing in inflammation and ophthalmology, announced the successful closure of a financing round to advance its lead compound, N0651, towards a Phase 2 clinical trial. This funding will support the compound’s progression through…